Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Novo Nordisk's type 2 diabetes drug, Ozempic, is the main competition for Lilly's Mounjaro ... It's likely, therefore, that steep tariffs on products imported to the U.S. from Denmark would ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

through existing Distribution and Promotion Agreements with Lilly, India. “The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood ...

which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and differentiate its products to stay ahead of the competition.

Eli Lilly and Company discovers ... and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt ...

Competitors are developing their own innovative treatments, which could potentially erode Eli Lilly's dominance in the diabetes and obesity sectors. The company will need to continuously innovate and ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration ... annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs ...

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin ...